Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Long Term Antiretroviral Therapy Could Restore Normal CD4 Cell Counts In HIV Positive Patients

19.07.2007
HIV positive patients who take combination antiretroviral therapy (cART) to combat HIV infection could see the numbers of CD4 cells in their immune system rise to concentrations found in HIV negative individuals, if they remain on the therapy for long enough and their HIV viral load load is suppressed to below 50 copies per ml. The findings are reported in an Article published early Online and in an upcoming edition of the Lancet.

However an accompanying Comment cautions the findings are only applicable to patients having periods of maximum virological suppression, and thus have limited application in low income countries.

Dr Amanda Mocroft, Royal Free Centre for HIV Medicine, Royal Free and University College London Medical Schools, and colleagues did a study of 1835 antiretroviral-naive patients from EuroSIDA, a pan-European observational cohort study. These patients, with a mean CD4 cell count of 204 cells per microlitre of blood, then started cART. They were selected because they all responded well to cART and their HIV viral loads were suppressed to below 50 copies per ml for extended periods of time.

The researchers found that the greatest average yearly increase in CD4 count of 100 cells per microlitre was seen in the year immediately following the start of cART. Significant, but lower, yearly increases of around 50 cells per microlitre were seen even five years after beginning cART in some cases, in which patients whose current CD4 count was below 500 cells per microlitre. Patients starting cART with low CD4 cell counts (of less than 200 cells per microlitre) had substantial rises in CD4 counts even after five years. The only groups without substantial increases in CD4 count were those where cART had been taken for more than five years with a current CD4 count of more than 500 cells per microlitre.

The authors conclude: “Normalisation of CD4 counts in HIV-infected patients for all infected individuals might be achievable if viral suppression with cART can be maintained for a sufficiently long period of time.

“We have shown that most patients with HIV who can maintain viral load at less than 50 copies per ml continue to have significant rises in CD4 counts, even after protracted exposure to combination therapy.

“Patients who started cART with a CD4 cell count of more than 350 cells per microlitre had CD4 cells counts approaching the level seen in HIV-negative individuals after more than three years of cART and had no further significant rises in CD4 counts.”

In the accompanying Comment, Dr Gary Maartens and Dr Andrew Boulle, University of Cape Town, South Africa, point out that CD4 cell count when patients start cART is the most important factor is predicting survival – not count increases after cART has begun.

They say: “Mocroft and colleagues’ findings that CD4 counts continue to increase on cART until normal values are reached, even with low CD4 counts at baseline, is only generalisable to patients on cART during periods of maximum virological suppression.”

They conclude: “Nevertheless, the researchers have shown that at least for patients with ideal responses to cART, normalisation of CD4 counts is likely to be achievable across a range of baseline counts.”

Tony Kirby | alfa
Further information:
http://www.thelancet.com

More articles from Health and Medicine:

nachricht Penn vet research identifies new target for taming Ebola
12.01.2017 | University of Pennsylvania

nachricht The strange double life of Dab2
10.01.2017 | University of Miami Miller School of Medicine

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Interfacial Superconductivity: Magnetic and superconducting order revealed simultaneously

Researchers from the University of Hamburg in Germany, in collaboration with colleagues from the University of Aarhus in Denmark, have synthesized a new superconducting material by growing a few layers of an antiferromagnetic transition-metal chalcogenide on a bismuth-based topological insulator, both being non-superconducting materials.

While superconductivity and magnetism are generally believed to be mutually exclusive, surprisingly, in this new material, superconducting correlations...

Im Focus: Studying fundamental particles in materials

Laser-driving of semimetals allows creating novel quasiparticle states within condensed matter systems and switching between different states on ultrafast time scales

Studying properties of fundamental particles in condensed matter systems is a promising approach to quantum field theory. Quasiparticles offer the opportunity...

Im Focus: Designing Architecture with Solar Building Envelopes

Among the general public, solar thermal energy is currently associated with dark blue, rectangular collectors on building roofs. Technologies are needed for aesthetically high quality architecture which offer the architect more room for manoeuvre when it comes to low- and plus-energy buildings. With the “ArKol” project, researchers at Fraunhofer ISE together with partners are currently developing two façade collectors for solar thermal energy generation, which permit a high degree of design flexibility: a strip collector for opaque façade sections and a solar thermal blind for transparent sections. The current state of the two developments will be presented at the BAU 2017 trade fair.

As part of the “ArKol – development of architecturally highly integrated façade collectors with heat pipes” project, Fraunhofer ISE together with its partners...

Im Focus: How to inflate a hardened concrete shell with a weight of 80 t

At TU Wien, an alternative for resource intensive formwork for the construction of concrete domes was developed. It is now used in a test dome for the Austrian Federal Railways Infrastructure (ÖBB Infrastruktur).

Concrete shells are efficient structures, but not very resource efficient. The formwork for the construction of concrete domes alone requires a high amount of...

Im Focus: Bacterial Pac Man molecule snaps at sugar

Many pathogens use certain sugar compounds from their host to help conceal themselves against the immune system. Scientists at the University of Bonn have now, in cooperation with researchers at the University of York in the United Kingdom, analyzed the dynamics of a bacterial molecule that is involved in this process. They demonstrate that the protein grabs onto the sugar molecule with a Pac Man-like chewing motion and holds it until it can be used. Their results could help design therapeutics that could make the protein poorer at grabbing and holding and hence compromise the pathogen in the host. The study has now been published in “Biophysical Journal”.

The cells of the mouth, nose and intestinal mucosa produce large quantities of a chemical called sialic acid. Many bacteria possess a special transport system...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

12V, 48V, high-voltage – trends in E/E automotive architecture

10.01.2017 | Event News

2nd Conference on Non-Textual Information on 10 and 11 May 2017 in Hannover

09.01.2017 | Event News

Nothing will happen without batteries making it happen!

05.01.2017 | Event News

 
Latest News

Water - as the underlying driver of the Earth’s carbon cycle

17.01.2017 | Earth Sciences

Interfacial Superconductivity: Magnetic and superconducting order revealed simultaneously

17.01.2017 | Materials Sciences

Smart homes will “LISTEN” to your voice

17.01.2017 | Architecture and Construction

VideoLinks
B2B-VideoLinks
More VideoLinks >>>